Table 2.
Patient- and tumor characteristics in relation to post-treatment tissue cholesterol
| Cholesterol-low | Cholesterol-rich | P value | |
|---|---|---|---|
| n = 28 | n = 14 | ||
| Age years (median) | 63.0 | 67.5 | 0.97 |
| Tumor size mm (median) | 22.5 | 20.5 | 0.47 |
| Tumor grade (NHG) | 0.26 | ||
| 1 | 7 | 2 | |
| 2 | 12 | 5 | |
| 3 | 9 | 7 | |
| Mitotic index | 0.10 | ||
| 1 | 17 | 5 | |
| 2 | 4 | 1 | |
| 3 | 7 | 7 | |
| ER (n = 31) | 0.31 | ||
| Positive | 21 | 7 | |
| Negative | 1 | 2 | |
| PR (n = 31) | 0.14 | ||
| Positive | 19 | 6 | |
| Negative | 3 | 3 | |
| HER2 (n = 30) | 0.97 | ||
| 0 | 5 | 2 | |
| 1+ | 7 | 3 | |
| 2+ | 5 | 3 | |
| 3+ | 4 | 1 | |
| Ki67 index (n = 26) | 0.02* | ||
| Low | 14 | 1 | |
| High | 5 | 6 | |
| HMGCR (n = 38) | 0.87 | ||
| Negative | 10 | 4 | |
| Positive | 16 | 8 | |
| Serum lipid levels, median (n = 42) | |||
| LDL pre-treatment | 3.76 | 3.21 | 0.20 |
| HDL pre-treatment | 1.60 | 1.41 | 0.54 |
| Cholesterol pre-treatment | 6.10 | 5.20 | 0.08 |
| Apoliporotein B pre-treatment | 1.07 | 0.91 | 0.11 |
| Apolipoprotein A1 pre-treatment | 1.65 | 1.72 | 0.84 |
| LDL post-treatment | 1.76 | 1.66 | 0.73 |
| HDL post-treatment | 1.58 | 1.51 | 0.56 |
| Cholesterol post-treatment | 3.70 | 3.45 | 0.47 |
| Apolipoprotein B post-treatment | 0.60 | 0.55 | 0.38 |
| Apolipoprotein A1 post-treatment | 1.58 | 1.51 | 0.45 |
NHG Nottingham histologic grade I-III (post-treatment pathological report), mitotic index according to Nottingham criteria (post-treatment pathological report), baseline tumor data (pretreatment): Ki67 high if > 20%, HMGCR positive if any cytoplasmic staining, ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) P values: Mann Whitney U test, linear-by-linear association chi-square test